• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Veru Inc.

    7/15/25 4:23:33 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VERU alert in real time by email
    DEFA14A 1 ef20052032_defa14a.htm DEFA14A
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of the Securities
    Exchange Act of 1934

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐
    Preliminary Proxy Statement

    ☐
    Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2))

    ☐
    Definitive Proxy Statement

    ☒
    Definitive Additional Materials

    ☐
    Soliciting Material under §240.14a-12

    VERU INC.
    (Name of Registrant as Specified in Its Charter)

     
    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

    Payment of filing fee (Check all boxes that apply):
     
    ☒
    No fee required.
     
    ☐
    Fee paid previously with preliminary materials.
     
    ☐
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
     


    VERU INC.
     
    SUPPLEMENT TO THE PROXY STATEMENT FOR THE
     
    SPECIAL MEETING OF SHAREHOLDERS
    TO BE HELD ON JULY 25, 2025
     
    This Supplement dated July 15, 2025 amends and supplements the Proxy Statement of Veru Inc. (“we” or “Veru”) dated June 10, 2025 (the “Proxy Statement”), with the following information.
     
    Appointment of Proxy Solicitor

    We have hired Morrow Sodali LLC to solicit proxies with respect to the Special Meeting. We will pay Morrow Sodali LLC a fee of $12,500, plus reasonable expenses. Morrow Sodali LLC will, among other things, provide advice regarding proxy solicitation issues and solicit proxies from our shareholders on our behalf in connection with the Special Meeting.
     
    Important Information

    Veru has filed a definitive Proxy Statement with the Securities and Exchange Commission (“SEC”) and has furnished to its shareholders a Proxy Statement in connection with the solicitation of proxies for the Special Meeting.  Veru advises its shareholders to read the Proxy Statement relating to the Special Meeting, as amended and supplemented by this Supplement, because it contains important information.
     
    Except as described in this supplement, none of the items or information presented in the Proxy Statement is affected by this supplement. This supplement does not provide all of the information that is important to your voting decisions at the Special Meeting. The Proxy Statement contains other important additional information. We encourage you to carefully read this supplement together with the Proxy Statement.
     
    Your vote is important, no matter how many or how few shares you may own.  If you have not already done so, please vote TODAY by telephone, via the Internet, or by signing, dating and returning the proxy card or voting instruction card previously mailed to you.  If you have already returned your proxy or voting instruction card or voted by telephone or via Internet, you do not need to take any action unless you wish to change your vote.
     

    2

    Get the next $VERU alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VERU

    DatePrice TargetRatingAnalyst
    5/14/2024$5.00Buy
    B. Riley Securities
    3/28/2024$3.00Outperform
    Raymond James
    6/7/2023$1.00Underperform → Hold
    Jefferies
    More analyst ratings

    $VERU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity

    MIAMI, FL, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced a successful meeting with FDA providing regulatory clarity for enobosarm, a selective androgen receptor modulator, as a muscle preservation drug product candidate in combination with GLP-1 RA for greater weight loss for the treatment of obesity. Highlights from FDA meeting The regulatory landscape continues to evolve for muscle preservation drugs in the treatment of obesity. Based on FDA feedback on Veru's clinical development program for enobosarm,

    9/23/25 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress

    --Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal side effects compared to semaglutide alone-- --Company reported positive efficacy and safety data from Phase 2b QUALITY Maintenance Extension study showing enobosarm significantly reduced body weight regain, prevented fat regain, and preserved lean mass after semaglutide discontinuation-- --Company has selected a novel modified release oral enobosarm formulation following pharmacokinetic clinical study-- --Company anticipates FDA feedback to clarify the regulatory pathway for enobosarm to preserv

    8/12/25 6:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru's Enobosarm, Utilizing Laxxon's SPID®-Technology

    Laxxon Medical Corp., a leading pharmaceutical technology company pioneering a new generation of advanced oral drug delivery systems, today announced that Veru Inc. (NASDAQ:VERU), a late clinical-stage biopharmaceutical company advancing treatments for cardiometabolic and inflammatory diseases, has selected a novel modified-release oral formulation of enobosarm that will utilize Laxxon's proprietary SPID® (Screen Printing Innovation Drug)-Technology. The novel tablet formulation achieved the desired target release profile, including a reduced maximum plasma concentration (Cmax), a delayed time to maximum plasma concentration (Tmax), a distinct secondary peak plasma concentration, and a si

    8/11/25 4:01:00 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Rankowitz Michael L

    4 - VERU INC. (0000863894) (Issuer)

    10/3/25 5:24:30 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hyun Grace

    4 - VERU INC. (0000863894) (Issuer)

    10/3/25 5:14:54 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Lu Lucy

    4 - VERU INC. (0000863894) (Issuer)

    10/3/25 5:06:21 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    SEC Filings

    View All

    Veru Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - VERU INC. (0000863894) (Filer)

    9/26/25 8:59:47 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru Inc. filed SEC Form 8-K: Other Events

    8-K - VERU INC. (0000863894) (Filer)

    8/27/25 4:05:03 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Veru Inc.

    10-Q - VERU INC. (0000863894) (Filer)

    8/12/25 10:44:27 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Veru with a new price target

    B. Riley Securities initiated coverage of Veru with a rating of Buy and set a new price target of $5.00

    5/14/24 8:03:44 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Veru with a new price target

    Raymond James initiated coverage of Veru with a rating of Outperform and set a new price target of $3.00

    3/28/24 7:50:24 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru upgraded by Jefferies with a new price target

    Jefferies upgraded Veru from Underperform to Hold and set a new price target of $1.00

    6/7/23 7:41:34 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ENTADFI issued to VERU INC

    Submission status for VERU INC's drug ENTADFI (ORIG-1) with active ingredient FINASTERIDE;TADALAFIL has changed to 'Approval' on 12/09/2021. Application Category: NDA, Application Number: 215423, Application Classification: Type 4 - New Combination

    12/13/21 8:12:46 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rankowitz Michael L bought $84,351 worth of shares (150,000 units at $0.56), increasing direct ownership by 150% to 250,000 units (SEC Form 4)

    4 - VERU INC. (0000863894) (Issuer)

    2/20/25 10:00:11 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fisch Harry bought $5,000 worth of shares (4,000 units at $1.25), increasing direct ownership by 0.52% to 774,736 units (SEC Form 4)

    4 - VERU INC. (0000863894) (Issuer)

    5/28/24 5:04:02 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barnette K Gary bought $6,696 worth of shares (5,000 units at $1.34) (SEC Form 4)

    4 - VERU INC. (0000863894) (Issuer)

    5/24/24 6:57:00 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    Financials

    Live finance-specific insights

    View All

    Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress

    --Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal side effects compared to semaglutide alone-- --Company reported positive efficacy and safety data from Phase 2b QUALITY Maintenance Extension study showing enobosarm significantly reduced body weight regain, prevented fat regain, and preserved lean mass after semaglutide discontinuation-- --Company has selected a novel modified release oral enobosarm formulation following pharmacokinetic clinical study-- --Company anticipates FDA feedback to clarify the regulatory pathway for enobosarm to preserv

    8/12/25 6:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru to Report Fiscal 2025 Third Quarter Financial Results on August 12th

    MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Tuesday, August 12, 2025, at 8:00 a.m. ET to discuss its fiscal 2025 third quarter financial results and to provide a business update. The audio webcast will be accessible under the Home page and Investors page of the Company's website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru Inc. call

    8/5/25 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

    --Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second quarter of calendar 2025 -- --With positive Phase 2b QUALITY study, Veru plans for end of Phase 2 meeting with FDA to discuss Phase 3 clinical program -- --Company to host conference call and webcast today at 8:00 a.m. ET-- MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced financial results for

    5/8/25 6:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Veru Inc.

    SC 13G/A - VERU INC. (0000863894) (Subject)

    11/12/24 9:34:37 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Veru Inc.

    SC 13G/A - VERU INC. (0000863894) (Subject)

    11/4/24 4:19:00 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Veru Inc.

    SC 13G - VERU INC. (0000863894) (Subject)

    4/24/24 4:16:01 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    Leadership Updates

    Live Leadership Updates

    View All

    Veru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory Board

    MIAMI, FL, June 01, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-related diseases, today announced the appointment of Erik Swenson, M.D., a world-renowned pulmonologist specializing in critical care, and Robert Schooley, M.D., an accomplished infectious disease physician and researcher, to its Infectious Disease Scientific Advisory Board (SAB) to join David D. Ho, M.D., a trailblazer of infectious disease viral research and therapeutic development, who is Chairman of the SAB. "We are pleased to share that Dr. Erik Swenson and

    6/1/23 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board

    MIAMI. FL, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced the appointment of David D. Ho, M.D., a trailblazer of infectious disease viral research and therapeutic development, as Chairman of its Scientific Advisory Board (SAB). "Today's appointment of Dr. Ho as Chairman of Veru's SAB illustrates our commitment to building a team of scientific experts to support our goal of developing and delivering life-saving therapies to patients with COVID-19 and other viral ARDS-related diseases," said Mitchell Steiner, M.D., Chairman, Presi

    1/10/23 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru Announces Appointment of Jason Davies to Lead EMEA, LATAM and APAC Infectious Disease Franchise for Veru International Focused on Hospitalized COVID-19 Patients

    MIAMI, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced the appointment of Jason Davies as Executive Vice President – General Manager of Europe, the Middle East and Africa (EMEA), Latin America (LATAM), and Asia Pacific (APAC) for Veru's Infectious Disease Franchise for Veru International. Most recently Mr. Davies had been the EMEA Head of Launch Excellence – Pharmaceutical Portfolio at Janssen (Johnson & Johnson) where he was responsible for creating and leading a new organization to enhan

    8/19/22 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care